H.R. 413 · 113th Congress
To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective…
Full title
To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 113th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
WelchSponsor3 cosponsors · 2 D, 1 R
3 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Amends the American Taxpayer Relief Act of 2012 to eliminate the two-year delay (until January 1, 2016) of the authority of the Secretary of Health and Human Services (HHS) to implement oral-only End Stage Renal Disease (ESRD)-related drugs in the ESRD prospective payment system (PPS) under title XVIII (Medicare) of the Social Security Act.
What it does: CRS summary · Introduced in House · Jan 23, 2013
Amends the American Taxpayer Relief Act of 2012 to eliminate the two-year delay (until January 1, 2016) of the authority of the Secretary of Health and Human Services (HHS) to implement oral-only End Stage Renal Disease (ESRD)-related drugs in the ESRD prospective payment system (PPS) under title XVIII (Medicare) of the Social Security Act. (Thus authorizes the Secretary to implement such drugs in the ESRD-PPS immediately.)
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.
Latest action (Feb 8, 2013): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Jan 23, 2013
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.